In December 2024, Pieris Pharmaceuticals merged with Palvella Therapeutics, Inc. Palvella Therapeutics, Inc. (Nasdaq: PVLA), is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies.
For more information about the Company and updates, please visit www.palvellatx.com
Company Details
- Employees
- 20
- Founded
- -
- Address
- 225 Franklin Street, Boston,massachusetts 02110,united States
- Phone
- 118572468998
- in****@****ris.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- pieris.com
- Keywords
- biotechnology research.
- HQ
- Boston, Massachusetts
Pieris Pharmaceuticals Questions
Pieris Pharmaceuticals's helpline number is 118572468998
Pieris Pharmaceuticals's website is pieris.com
Pieris Pharmaceuticals's LinkedIn profile is https://www.linkedin.com/company/pieris-pharma
Pieris Pharmaceuticals has
20 employees.
View email and phone details for 20
employees at Pieris Pharmaceuticals.
Pieris Pharmaceuticals's industry is
Biotechnology Research
Pieris Pharmaceuticals's top competitors are
Morphosys,
Medigene Ag,
Autobahn Therapeutics, Inc.,
Mira Pharmaceuticals,
Proteros Biostructures Gmbh,
Immatics,
Formycon Ag,
Iomx Therapeutics Ag,
Coriolis Pharma,
Palvella Therapeutics.
Pieris Pharmaceuticals's support email address is info@pieris.com
Pieris Pharmaceuticals's categories are Biotechnology Research
Pieris Pharmaceuticals's founding year is 2015
